Tezspire delivers sustained remission in eosinophilic esophagitis

Tezspire (tezepelumab-ekko) demonstrated significant and sustained improvements across key measures of eosinophilic esophagitis (EoE) in the phase 3 CROSSING trial, highlighting its potential as a new biologic treatment option for patients whose disease remains inadequately controlled with current therapies.

At 24 weeks, approximately two-thirds of patients receiving tezepelumab achieved histologic remission, compared with 3.5% of those receiving placebo. Treatment also led to greater reductions in dysphagia symptoms, reflecting meaningful improvement in the frequency and severity of swallowing difficulties.

Benefits were maintained through 52 weeks. Histologic remission was achieved in 67.8% (210 mg dose) and 63.3% (420 mg dose) of tezepelumab-treated patients versus 5.4% with placebo, while improvements in dysphagia scores remained significantly greater than those seen with placebo.

Tezepelumab also improved endoscopic measures of disease activity. By week 52, total endoscopic remission, defined as the absence of visible inflammatory or structural features of EoE, was achieved in 34.4% (210 mg dose) and 29.5% (420 mg dose) of treated patients compared with 4.1% of placebo recipients.

Notably, these benefits were observed even though patients were allowed to continue stable background EoE therapies, including proton pump inhibitors and swallowed topical corticosteroids. The safety profile was consistent with approved indications for tezepelumab, with nasopharyngitis, headache, and diarrhea among the most commonly reported adverse events.

What's next?

Tezepelumab is not currently approved for EoE. The positive phase 3 results support continued regulatory development and suggest that targeting thymic stromal lymphopoietin (TSLP), an upstream driver of inflammation, may offer a new approach for managing this chronic, increasingly common disease.

Source: Amgen. (2026 Oct 20). Tezspire delivered histologic remission and symptom improvement in eosinophilic esophagitis